Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis.

ABSTRACT:

Background

Advances in the availability and regimen optimization of highly effective disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (RRMS) have led to questions about their comparative worth.

Objectives

This study evaluates the costs and effects of natalizumab versus other highly effective DMTs and the impact, in terms of times and costs, of the new subcutaneous natalizumab formulation versus the intravenous formulation in patients with RRMS in Italy.

Methods

This is a cost-consequence analysis from the Italian national health service and societal perspectives. A Markov model was developed to assess clinical and cost outcomes related to disease and DMTs. The model simulated two scenarios: one comparing natalizumab extended-dose regimen

SUBMITTER: Prosperini L 

PROVIDER: S-EPMC12602592 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature